Menu
Washingtoner
  • Home
  • Health
  • Technology
  • Artificial Intelligence
  • Entertainment
  • Non-profit
  • Real Estate
  • Music
  • Software
Washingtoner

Orlance, Inc. awarded RNA Vaccine Development Grant
Washingtoner/10263081

Trending...
  • Qscription Technologies and NEOPATHOLOGY CORP. Sign MOU to Bring FDA-Cleared Lung Imaging AI into U.S. Clinical Practice
  • OneVizion Launches Vera AI, Bringing Connected Operational Context to Infrastructure Teams
  • Applicants Sought for the Tacoma Arts Commission and the Tacoma Creates Advisory Board
SEATTLE, July 10, 2024 ~ Seattle-based biotech company, Orlance, Inc., has recently been granted a Phase I Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH). The grant, worth $300,000 per year for two years, will be used to develop and optimize RNA vaccine formulations using Orlance's needle-free MACH-1™ platform.

The MACH-1 platform aims to enhance the safety, stability, and efficacy of RNA vaccines for infectious diseases such as influenza and Covid-19, as well as cancer immunotherapy applications. This technology represents a significant advancement in RNA vaccine delivery compared to traditional methods.

Unlike traditional lipid nanoparticle (LNP) RNA vaccine formulations that require ultra-cold storage and have been associated with rare adverse events like myocarditis, the MACH-1 platform utilizes dry, stable RNA-coated gold microparticles. These microparticles are propelled directly into the epidermis using a burst of pressurized gas. Once they penetrate the skin's outermost layer, they are taken up by immune cells that reside there.

More on Washingtoner
  • International Society of Medical AI Convenes Global Faculty in Florence for ISMAI 2026
  • Boston Industrial Solutions Introduces Personalized Printing Training
  • Century Fasteners de Mexico Exhibiting at the 2026 Automotive & Aerospace Nearshoring Summit
  • Spokane: Funding Available for Tourism and Culture Investment Grants
  • Retell AI White Label Platform for Agencies Launched by VoiceAIWrapper, With Branded Client Portals and No Per-Minute Markup

This needle-free and painless delivery system not only ensures better stability at ambient temperatures but also provides significant supply chain advantages in both developed and low-resource settings. Additionally, it can significantly improve patient comfort and compliance associated with discomfort and fear of needle-based injections.

The SBIR-funded project, titled "Gene Gun-delivered RNA vaccines," will be led by Orlance Principal Investigators Hannah Frizzell, PhD and Kenneth Bagley, PhD. The team aims to optimize RNA formulations for MACH-1 gene gun delivery that maximize loading, maintain functional integrity, and ensure stability and immunogenicity. They will also compare the effectiveness of MACH-1 delivered RNA vaccines against traditional LNP/RNA vaccines in inducing immune responses in preclinical models.

Preliminary studies have shown promising results with MACH-1 delivered RNA vaccines achieving comparable immunogenicity to LNP/RNA vaccines with significantly lower doses. Orlance co-founder and CEO, Kristyn Aalto, explains that while mRNA vaccines have shown great potential in recent years, there is still significant work to be done to improve their utility and global health impact.

More on Washingtoner
  • FOCUS Names Mark Phillips Senior Vice President of Business Development
  • Notaron Expands Online Notarization Access Following Wisconsin Approval
  • Wings Air Helicopters Selected to Support VIP Transportation for Resorts World in New York
  • Scoop Social Co. Brings Its Signature Mobile Dessert Experience to Houston This October
  • Spokane: Construction Will Require Temporary Browne Street Lane Reductions

The grant will enable Orlance to conduct crucial preclinical studies and pave the way for subsequent phases of development, ultimately leading to clinical trials. Aalto also mentions that Orlance already has a well-developed MACH-1 DNA vaccine candidate portfolio and offering both DNA and RNA vaccine options allows them to provide ideal solutions for specific indications.

Founded in 2016 as a spin-out from the University of Washington (UW), Orlance is focused on developing next-generation MACH-1 vaccines and cancer immunotherapies. With $13M in SBIR funding awarded to date, the company has made significant progress towards readiness for initial regulatory filings in 2024. They plan to initiate Phase I clinical trials for their lead infectious disease asset in 2025 and are actively partnering with other vaccine developers to develop MACH-1 vaccine and immunotherapy candidates across multiple indications.

Orlance's MACH-1 platform has the potential to revolutionize RNA vaccine delivery, making it safer, more stable, and more effective. With the support of NIH's SBIR grant, Orlance is one step closer to achieving their goal of improving global health through innovative genetic vaccines.
Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on Washingtoner
  • Allstream Energy Partners Nominated in Multiple Categories for Fast Company's Best Workplaces for Innovators
  • Pebble Photo Booths Brings Modern Photo Experiences to Vancouver, Washington
  • Spokane: Flags at Half-Staff in Remembrance of 9/11 Victims
  • Haven Treatment Center Now In-Network with First Choice, Expanding Access to Youth Health
  • Kerri Lawless Introduces New Home-Selling Option for Local Homeowners
  • FDA-Cleared Zeta TMS Robotic System Moves Toward Deployment as FDA, DARPA and Commercial Catalysts Converge: NRx Pharmaceuticals (N A S D A Q: NRXP)
  • Baird Medical Turns Global Expansion Into Tangible Growth: N A S D A Q: BDMD Posts 25% Revenue Surge as U.S. and International Markets Accelerate
  • City of Spokane Launches 'Emergency Streets' Pilot Program
  • Spokane: City Seeks Feedback on Future Land Use Map
  • Shelter Structures America makes European debut at TEMPOR EXPO 2026 in Fulda, Germany
  • Longevity Academy Announces J.P. Medved of Longevity Advice as Next Guest in the Longevity Leaders
  • Medcurity Introduces a Better Way for Healthcare and Its Vendors to Build Trust
  • Haven Treatment Center Now In-Network Partnership with Aetna, Expanding Access to Youth Health Care
  • Applicants Sought for the Tacoma Arts Commission and the Tacoma Creates Advisory Board
  • Spokane City Council Approves Emergency Tenant Protections
  • HydroExcavation.com Relaunches With Exclusive Local Service Areas and Dedicated Hydrovac Manufacturer Directory
  • Sky Quarry Enters a Powerful New Chapter: Refinery Restart Emminent, Nevada Oil Initiative and Visibility Put (NAS DAQ: SKYQ) in the Spotlight
  • Intelligence Daily Features Veteran Hollywood Producer Kirk Shaw On AI And The Future Of Entertainment
  • OneVizion Launches Vera AI, Bringing Connected Operational Context to Infrastructure Teams
  • P-Wave Press Announces Pushing the Wave 2025 by L.A. Davenport
_catLbl0 _catLbl1

Popular on Washingtoner

  • Popular AI planner Voiset launches version 2.0 and enters MENA at LEAP 2026 with full Arabic support - 235
  • Diginyze eCommerce ERP Module Creates Single Source of Truth for Enterprise Operations - 156
  • Continuous You Foundation Opens Applications For A 100-year Artist Grant - 138
  • 3ptechies Partners with Coolmuster to Give Away Data Recovery Software Licenses - 130
  • Tacoma: Applications Now Being Accepted for a Position on the Planning Commission - 126
  • Break the Resume Mold: Career Valet Changes How Executives Hunt for Jobs - 125
  • Tacoma: Hylebos Bridge Closed Today for Maintenance Work - 115
  • DuoKey launches the World's First Agentic Crypto Agility Platform - 114
  • Dr. Pen Official Introduces Advanced Microneedling Technology for Precision Skincare at Home
  • Marti Reeder Ranked Among Washington State's Top Real Estate Brokers by RealTrends Verified

Similar on Washingtoner

  • Retell AI White Label Platform for Agencies Launched by VoiceAIWrapper, With Branded Client Portals and No Per-Minute Markup
  • Notaron Expands Online Notarization Access Following Wisconsin Approval
  • Wings Air Helicopters Selected to Support VIP Transportation for Resorts World in New York
  • Scoop Social Co. Brings Its Signature Mobile Dessert Experience to Houston This October
  • The Social Capital Revolution Comes to Phoenix!
  • Super Rooter Expands to 190 Plumbing, Sewer, and Drain Service Locations Across the United States
  • European Patent for ALS Program Expands the Story: HOPE Deploys Robotic TMS & FDA Commercialization Path Advances: NRx Pharmaceuticals: NAS DAQ: NRXP
  • Congressman Chuck Edwards (NC-11) Presents ReadyCommunities Partnership 2026 National Service Award to Local Businessman / US Air Force Veteran
  • FDA-Cleared Zeta TMS Robotic System Moves Toward Deployment as FDA, DARPA and Commercial Catalysts Converge: NRx Pharmaceuticals (N A S D A Q: NRXP)
  • Baird Medical Turns Global Expansion Into Tangible Growth: N A S D A Q: BDMD Posts 25% Revenue Surge as U.S. and International Markets Accelerate
Copyright © 2026 washingtoner.com | Terms of Service | Privacy Policy | Contact Us | Contribute